Business
Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
- Net product sales for LIVMARLI® (maralixibat) oral solution totaled $18.8 million in the third quarter of 2022 and $47.2 million year-to-date - Mirum
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Net product sales for LIVMARLI® (maralixibat) oral solution totaled $18.8 million in the third quarter of 2022 and $47.2 million year-to-date\n\n- Mirum raises 2022 full year net product sales guidance estimate for LIVMARLI to $70 million\n\n- Conference call to provide business updates today, November 9 at 5:00 a.m. PT/8:00 a.m. ET\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter ended September 30, 2022 and provided a business update.\n\n“The Mirum team achieved multiple key milestones on top of continued commercial growth this quarter, setting us up for a strong finish to 2022. We are well positioned for European approval by the end of the year with our recent positive CHMP opinion. Our revenues continue to grow in what has been an excellent rare disease launch,” said Chris Peetz, president and chief executive officer of Mirum. “Finally, our positive Phase 3 study results in PFIC validate our efficacy strategy across the highly burdensome cholestatic diseases we are studying.”\n\nKey Operational Highlights\n\n\nAnnounced positive topline data from LIVMARLI Phase 3 MARCH study in progressive familial intrahepatic cholestasis (PFIC).\n\n\nAnnounced positive CHMP opinion for LIVMARLI for cholestatic pruritus in patients with Alagille syndrome (ALGS) two months of age and older.\n\n\nAnnounced approval of LIVMARLI for cholestatic pruritus in patients with ALGS in Israel.\n\n\nPresented key data at recent medical conferences, including:\n\n\nNASPGHAN:\n\n\nSix-year natural history comparison with LIVMARLI in ALGS.\n\n\nHealth-related quality of life impact on caregivers of children with ALGS.\n\n\nFour-year growth improvement in ALGS with LIVMARLI.\n\n\n\n\nThe Liver Meeting of AASLD:\n\n\nOral late-breaker featuring MARCH PFIC data; selected as ‘Best of the Liver Meeting.’\n\n\nLate-breaker poster highlighting safety and efficacy data for LIVMARLI from RISE infant safety study in ALGS.\n\n\nReal-world evidence of LIVMARLI’s impact on patients with ALGS.\n\n\n\n\n\n\nBolstered balance sheet with public offering of common stock and net proceeds of $86.1 million.\n\n\n\nUpcoming Anticipated Milestones\n\n\nLIVMARLI\n\n\nAnticipate European Commission decision regarding approval of LIVMARLI for the treatment of cholestatic pruritus in pat...